Nephy Samuel

Nephy Samuel


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2022 in Cureus
Verified
Journal Article
Open access
MHMichael Horseman
Michael Horseman
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
ATAndrew S. Tenpas
Andrew S. Tenpas
RJRene Verduzco Jr.
Rene Verduzco Jr.
Salim SuraniSalim Surani
Salim Surani
Humans maintain core body temperature via a complicated system of physiologic mechanisms that counteract heat/cold fluctuations from metabolism, exertion, and the environment. Overextension of these mechanisms or disruption of body temperature homeostasis leads to bodily dysfunction, culminating in a syndrome analogous to exertional heat stroke (EHS). The inability of this thermoregulatory process to maintain the body temperature is caused by either thermal stress or certain drugs. EHS is a syndrome characterized by hyperthermia and the activation of systemic inflammation. Several drug-induced hyperthermic syndromes may resemble EHS and share common mechanisms. The purpose of this article is to review the current literature and compare exertional heat stroke (EHS) to three of the most widely studied drug-induced hyperthermic syndromes: malignant hyperthermia (MH), neuroleptic malignant syndrome (NMS), and serotonin syndrome (SS). Drugs and drug classes that have been implicated in these conditions include amphetamines, diuretics, cocaine, antipsychotics, metoclopramide, selective serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants (TCAs), and many more. Observations suggest that severe or fulminant cases of drug-induced hyperthermia may evolve into an inflammatory syndrome best described as heat stroke. Their underlying mechanisms, symptoms, and treatment approaches will be reviewed to assist in accurate diagnosis, which will impact the management of potentially life-threatening complications.

26 January 2021 in Medicina
Verified
Journal Article
Open access
PDF file
LPLadan Panahi
Ladan Panahi
GUGeorge Udeani
George Udeani
MHMichael Horseman
Michael Horseman
JWJaye Weston
Jaye Weston
NSNephy Samuel
Nephy Samuel
DBDaniela Bazan
Daniela Bazan
Traditionally, the management of patients with pulmonary embolism has been accomplished with anticoagulant treatment with parenteral heparins and oral vitamin K antagonists. Although the administration of heparins and oral vitamin K antagonists still plays a role in pulmonary embolism management, the use of these therapies are limited due to other options now available. This is due to their toxicity profile, clearance limitations, and many interactions with other medications and nutrients. The emergence of direct oral anticoagulation therapies has led to more options now being available to manage pulmonary embolism in inpatient and outpatient settings conveniently. These oral therapeutic options have opened up opportunities for safe and effective pulmonary embolism management, as more evidence and research is now available about reversal agents and monitoring parameters. The evolution of the pharmacological management of pulmonary embolism has provided us with better understanding regarding the selection of anticoagulants. There is also a better understanding and employment of anticoagulants in pulmonary embolism in special populations, such as patients with liver failure, renal failure, malignancy, and COVID-19.

1 November 2021 in Currents in Pharmacy Teaching and Learning
Verified
Journal Article
Closed access
SDSandy Diec
Sandy Diec
PPPooja Himangshu Patel
Pooja Himangshu Patel
NSNephy Samuel
Nephy Samuel
JHJose J. Hernandez-Munoz
Jose J. Hernandez-Munoz

26 July 2022
Verified
Book Chapter
Open access
PDF file
ATAndre Thomas
Andre Thomas
YLYun Li
Yun Li
CKChristine L. Kaunas
Christine L. Kaunas
MNMarty Newcomb
Marty Newcomb
GCGerard E. Carrino
Gerard E. Carrino
HCHector O. Chapa
Hector O. Chapa
Interprofessional education is required by all athletic training, medical, pharmacy, nursing, and public health students at Texas A&M University. One such opportunity for collaborative training has been Disaster Day, the nation’s largest student-led interprofessional emergency response simulation. This annual training of 500–800 students takes place on a single day, in two 4-h sessions, at a designated site on campus. Due to COVID-19, the simulation could not be offered in-person in 2020, so the organizers looked for alternative solutions. We opted to use digital games, which have been proposed and used for formal and informal education for several years. While there have been games specifically developed for interprofessional training, none of those games were readily available for use by other institutions, nor is their focus on disaster response. In this chapter, we provide a detailed analysis of how an interdisciplinary team of health professions educators and game designers met interprofessional learning requirements while maintaining student engagement. Lessons from an abbreviated schedule and limited budget will be discussed. The approach incorporated different technologies and tools that are readily available. We will discuss pitfalls, assumptions, and full implementation of our approach. This will allow others to replicate our method and create similar highly engaging learning experiences for remote and online learning.

15 April 2023 in Emergency Medicine International
Verified
Journal Article
Open access
PDF file
ABAlexandra Burum
Alexandra Burum
JCJasmine Carino
Jasmine Carino
MMMackenzie McBeth
Mackenzie McBeth
NSNephy Samuel
Nephy Samuel
THTrager D. Hintze
Trager D. Hintze
Atrial fibrillation (AF) is the most common cardiac arrhythmia encountered in the emergency department (ED) and when patients present in acute AF with rapid ventricular rate (RVR), it can result in significant morbidity and mortality. Primary treatment modalities are aimed at rate control with the two most common agents being intravenous metoprolol and diltiazem. Some evidence suggests that diltiazem may be more effective at controlling rate in these patients; however, the dosing strategies, pharmacologic differences, and study designs may play a role in the observation of these differences. The purpose of this article is to review the evidence for using weight-based metoprolol in the treatment of AF with RVR. The vast majority of studies comparing metoprolol and diltiazem for the treatment of acute AF with RVR compare a flat dose of metoprolol to a weight-based dose of diltiazem. Following a comprehensive review, only two studies have compared a weight-based dosing strategy of intravenous (IV) metoprolol versus IV diltiazem for this disease state. Overall, the two studies only contained 94 patients and failed to meet power. Beyond differing dosing strategies, differences in pharmacokinetics between the two medications (like the onset of action and metabolism) could have played a role in the differences observed in the studies. Further studies are warranted to provide better guidance on which agent should be used in the treatment of acute AF with RVR.